Americans as young as 18 with a chronic condition can now receive an RSV vaccine after Pfizer snagged expanded FDA approval ...

Thermo Fisher told investors it is ready to shut the door on 2024, anticipating biotech funding to improve and lingering ...

Antitrust regulators shouldn't clear Novo Holdings' planned acquisition of Catalent, Roche CEO Thomas Schinecker said ...

A venture capital firm that seeks to digitize the life sciences ecosystem has plans for a $500 million follow-up fund, ...

Alto Neuroscience’s stock tumbled 60% on Wednesday morning, the day after the company said a mid-stage trial for its oral ...

The UK medicines authority approved Eli Lilly’s Alzheimer’s drug Kisunla on Wednesday, making it the third major market to ...

A nimble Houston startup has raised a concise $28.4 million Series A to start a mid-stage trial. The company, named March ...

Merck is acquiring a startup spun out of Yale called Modifi Bio, which has developed a suite of molecules against ...

Roche’s competition in the eye disease space is intensifying with Renegeron’s high-dose Eylea and looming biosimilar ...

Eccogene's $60M milestone from AstraZeneca: The payment arrived after Eccogene met several milestones, including dosing the first ...

The eye drop maker Ocuphire Pharma and startup Opus Genetics are merging in an all-stock deal, the companies told Endpoints ...

Amgen is moving forward with the launch of Pavblu, its biosimilar to Regeneron's blockbuster Eylea, following an appeals ...